Palmitoylethanolamide (PEA) for Alzheimer's Disease
Also known as: PEA, Normast, Levagen
PEA reduces neuroinflammation — an early and persistent feature of Alzheimer's disease — through endocannabinoid system modulation.
Mechanism of Action
PEA activates PPARα in neurons and glial cells, suppressing NF-κB-driven inflammatory gene expression. It reduces mast cell-mediated neuroinflammation, modulates microglial phenotype toward anti-inflammatory state, and may enhance endocannabinoid tone for synaptic protection.
General mechanism: Endocannabinoid-like lipid. PPARα agonist, mast cell stabilizer, NF-κB inhibitor, neuroinflammation modulator.
Current Evidence
Small clinical studies show cognitive improvement in MCI/early AD with PEA supplementation. Anti-neuroinflammatory effects documented. Micronized PEA improves bioavailability.
Clinical Status: Small clinical studies positive. Micronized formulations available in Europe. Larger trials needed.
Safety Profile
Excellent safety. No psychoactive effects. No significant drug interactions. Micronized form improves absorption.
Key Research Questions
- Can PEA slow AD progression through anti-neuroinflammatory mechanisms?
- Does micronized PEA achieve therapeutic brain concentrations?